Create a sickle cell pain crisis pathway: triage priority, analgesia ladders, adjuvant…
- User
Create a sickle cell pain crisis pathway: triage priority, analgesia ladders, adjuvant therapies, and discharge supports.
- Assistant
Sickle Cell Pain Crisis (Vaso-Occlusive Crisis) Management Pathway
This pathway is designed for emergency department (ED) or acute care settings for adults and older children with sickle cell disease (SCD) presenting with acute pain crisis. It is based on NIH, BCSH, and ASH guidelines. Individualize care based on patient history, comorbidities, and known opioid tolerance. Rapid pain assessment and intervention within 30-60 minutes of arrival is critical.
1. Triage Priority
- ESI Level 2 (High Risk): All known SCD patients with pain crisis.
- Severe pain (≥7/10), frequent crises (>3/year), or high-risk features (chest pain, fever >38.5°C, hypoxia <92%, neurological symptoms).
- ESI Level 3: Mild-moderate pain (<7/10) in stable patients with infrequent crises.
- Immediate actions at triage:
- Vital signs, pain score (0-10 scale, preferably patient-specific tool like Adult Non-Oncologic Pain Scale).
- IV access, oxygen if SpO2 <92%.
- Notify hematology if available.
- Avoid delays; aim for analgesia within 30 min.
2. Initial Assessment (Within 15 min of Triage)
- History: Pain location/intensity, prior crises, home analgesia use, hydration status, triggers (dehydration, cold, stress).
- Exam: Focus on chest (acute chest syndrome risk), neuro, abdomen.
- Labs/Imaging (stat if indicated): CBC (Hb drop?), reticulocyte count, LDH, bilirubin, CRP, blood cultures if febrile, CXR if respiratory symptoms.
- Risk stratify:
Risk Level Features Disposition Low Mild pain, responds to home meds, Hb stable Oral analgesia, observe 1-2h, discharge if improved Moderate Moderate-severe pain, partial home response Admit for IV analgesia ± PCA High Severe pain, complications (ACS, stroke risk), Hb drop >2g/dL Admit to monitored bed/HDU, hematology consult
3. Analgesia Ladders
Use patient-reported pain score. Titrate to effect (≥2-point reduction). Account for opioid tolerance in frequent presenters. Reassess q30-60min.
Ladder Step Pain Score First-Line Alternatives/Dosing Examples (Adult) Escalation Step 1: Mild 1-3/10 Oral non-opioid Ibuprofen 400-600mg q6-8h OR paracetamol 1g q6h ↑ if no response in 30min Step 2: Moderate 4-6/10 Oral/IV opioid + non-opioid Oxycodone 5-10mg PO q4-6h OR IV morphine 0.1mg/kg (max 10mg) q30min PRN PCA if ongoing Step 3: Severe ≥7/10 IV opioid ± PCA IV hydromorphone 0.5-1mg q15-30min OR morphine 0.1-0.2mg/kg/hr infusion (start low, titrate)PCA: Morphine 1mg bolus, 10min lockout, 0.5-1mg/hr basal Add ketamine infusion (0.1-0.3mg/kg/hr) if opioid-resistant Step 4: Refractory Persistent ≥7/10 after Step 3 Multimodal Add IV ketamine bolus 0.3mg/kg + infusionOR regional (e.g., erector spinae block)Consult pain/hematology ICU if complications - Notes:
- Avoid meperidine (normeperidine toxicity risk).
- Ketorolac 30mg IV q6h (max 120mg/day, avoid if renal impairment).
- Anti-emetics: Ondansetron 4-8mg IV q8h PRN.
- Naloxone only for respiratory depression (<8/min).
4. Adjuvant Therapies
Initiate alongside analgesia:
- Hydration: IV D5 0.9% NaCl or 0.45% NaCl at 1-1.5x maintenance (avoid overhydration → ACS risk). Oral if tolerated.
- Oxygen: Target SpO2 ≥92-95%; nasal cannula 2-4L/min if hypoxic.
- Incentive Spirometry: q1-2h awake to prevent ACS (10 breaths/set).
- Warmth: Warm environment/packs for vaso-dilation.
- Other:
Therapy Indication Dosing Hydroxyurea Long-term (if not on) Continue home dose; initiate if eligible Antibiotics Fever or ACS suspicion Ceftriaxone 2g IV q24h ± macrolide Blood Transfusion Hb <6g/dL, ACS, stroke Simple or exchange PRBCs; consult hematology Magnesium Neuro symptoms 2g IV over 4h Dexamethasone Severe/refractory (controversial) 0.3mg/kg IV q12h x2 (peds)
5. Monitoring
- q1-2h: Pain score, vitals, sedation (Pasero scale), urine output.
- q4-6h: Labs if high-risk.
- Complications to watch: ACS (fever, chest pain, hypoxia), splenic sequestration, infection, avascular necrosis.
6. Discharge Supports
Criteria (all must be met):
- Pain ≤3/10 on oral analgesia x4-6h.
- Stable vitals (afebrile, SpO2 ≥92% RA, tolerating PO).
- Hb stable (±1g/dL), no new complications.
-
24h since last IV opioid dose.
Discharge Bundle:
- Analgesia: 3-7 day opioid script (e.g., oxycodone 5mg q4-6h PRN) + paracetamol/NSAID. Taper plan.
- Hydration: Oral fluids 2-3L/day.
- Spirometry: Device + education.
- Follow-up: Hematology clinic within 7 days; PCP if no hematologist. 24/7 crisis line.
- Education: Triggers avoidance, hydroxyurea adherence, vaccines.
- Red Flags: Return if pain > home baseline, fever, SOB, neuro changes.
- Social Supports: Link to SCD support groups, home health if frequent admissions.
Audit Metrics: Time to analgesia <30min, % admitted <24h, readmission <7 days.
Consult local protocols/hematology for variations. This is not medical advice; for training purposes.
- ESI Level 2 (High Risk): All known SCD patients with pain crisis.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.